Solara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, kindly note that the Company, as part of investors engagement activities, has scheduled a conference call with the investors and analysts on Friday, May 12, 2023, at 3:30 pm IST to discuss its Q4 financial results. Solara Active Pharma Sciences Ltd - 541540 - Board Meeting Intimation for Announcement Of Board Meeting Under Regulation 29 (1) Of SEBI Listing Regulations
Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2023 ,inter alia, to consider and approve the audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31, 2023, amongst other matters. Solara Active Pharma Sciences Ltd - 541540 - Statement On Deviation Or Variation Of Funds Raised Through Preferential Issue Of Convertible Warrants
We refer to your mail dated April 19, 2023, and wish to clarify that pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015 read with SEBI Circular No. CIRlCFD/CMDI116212019 dated December 24,2019, we hereby confirm that there is no deviation or variation in the use of funds raised through Preferential Issue of Convertible Warrants from the objects stated in the Explanatory Statement to the Notice of Extra-Ordinary General Meeting of the Company dated January 31, 2019. Solara Active Pharma Sciences Ltd - 541540 - Certificate From A Practising Company Secretary Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015
Please find attached herewith the necessary Certificate pursuant to Regulation 40(9) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for the financial year ended March 31, 2023. Solara Active Pharma Sciences Ltd - 541540 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanySolara Active Pharma Sciences Ltd 2CIN NO.L24230MH2017PLC291636 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY 0 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: S Murali Krishna Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: S Hariharan Designation: CFO EmailId: [email protected] Date: 13/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Solara Active Pharma Sciences Ltd - 541540 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation pursuant to Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Solara Active Pharma Sciences Ltd - 541540 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we are forwarding herewith a copy of Certificate received from M/s. CAMEO CORPORATE SERVICES LIMITED the Registrar and Share Transfer Agent of the Company, for the Quarter ended March 31, 2023, for your records. Solara Active Pharma Sciences Ltd - 541540 - Compliance Certificate For The Period Ended March 31, 2023
Pursuant to Regulation 7(3) of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, we are enclosing herewith Compliance Certificate for the Financial Year ended March 31, 2023, received from M/s. Cameo Corporate Services Limited the Registrar and Share Transfer Agent of the Company. Solara Active Pharma Sciences Ltd - 541540 - Closure of Trading Window
In accordance with the Company's Code of Conduct for Prohibition of Insider Trading, the trading window for dealing in the securities of the Company shall be closed for all Connected persons/Designated persons and their immediate relatives with effect from Saturday, April 01, 2023, till 48 hours from the date of declaration of audited financial results of the company for the quarter and year ended March 31, 2023. Solara Active Pharma Sciences Ltd - 541540 - Voting Results Of Postal Ballot And Scrutinizer'S Report.
We would like to inform you that the resolution Circulated via Postal Ballot Notice Dated January 25, 2023, has been passed by the Members of the Company by requisite majority. The resolutions are deemed as passed on the last date of the e-voting, i.e., Sunday, February 26, 2023.